In the Clinic7 May 2019
    Author, Article and Disclosure Information

    Recent guidelines on diagnosis and management of high blood pressure (BP) include substantial changes and several new concepts compared with previous guidelines. These are reviewed and their clinical implications are discussed in this article. The goal is to provide a practical reference to assist clinicians with up-to-date management of patients with high BP. Important issues include new diagnostic thresholds, out-of-office BP monitoring, intensified treatment goals, and a different approach to resistant hypertension. Finally, differences among guidelines, the persistent controversies that have led to them, and their implications for clinical practice are discussed.

    References

    • 1. Weir MR In the Clinic: hypertension. Ann Intern Med2014;161:ITC1-15. [PMID: 25437425]. doi:10.7326/0003-4819-161-11-201412020-01006 LinkGoogle Scholar
    • 2. Whelton PK Carey RM Aronow WS Casey DE Jr Collins KJ Dennison Himmelfarb C et al2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension2018;71:1269-324. [PMID: 29133354] doi:10.1161/HYP.0000000000000066 CrossrefMedlineGoogle Scholar
    • 3. Williams B Mancia G Spiering W Agabiti Rosei E Azizi M Burnier M et al2018 ESC/ESH guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens2018;36:1953-2041. [PMID: 30234752] doi:10.1097/HJH.0000000000001940 CrossrefMedlineGoogle Scholar
    • 4. Qaseem A Wilt TJ Rich R Humphrey LL Frost J Forciea MA Clinical Guidelines Committee of the American College of Physicians and the Commission on Health of the Public and Science of the American Academy of Family PhysiciansPharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med2017;166:430-7. [PMID: 28135725]. doi:10.7326/M16-1785 LinkGoogle Scholar
    • 5. Wilt TJ Kansagara D Qaseem A Clinical Guidelines Committee of the American College of PhysiciansHypertension limbo: balancing benefits, harms, and patient preferences before we lower the bar on blood pressure. Ann Intern Med2018;168:369-70. [PMID: 29357397]. doi:10.7326/M17-3293 LinkGoogle Scholar
    • 6. Miyazaki K Overdiagnosis or not? 2017 ACC/AHA high blood pressure clinical practice guideline: consequences of intellectual conflict of interest. J Gen Fam Med2018;19:123-6. [PMID: 29998041] doi:10.1002/jgf2.176 CrossrefMedlineGoogle Scholar
    • 7. Bell KJL Doust J Glasziou P Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med2018;178:755-7. [PMID: 29710197] doi:10.1001/jamainternmed.2018.0310 CrossrefMedlineGoogle Scholar
    • 8. Whelton PK Williams B The 2018 European Society of Cardiology/European Society of Hypertension and 2017 American College of Cardiology/American Heart Association blood pressure guidelines: more similar than different. JAMA2018;320:1749-50. [PMID: 30398611] doi:10.1001/jama.2018.16755 CrossrefMedlineGoogle Scholar
    • 9. Wright JT Jr Williamson JD Whelton PK Snyder JK Sink KM Rocco MV et alSPRINT Research GroupA randomized trial of intensive versus standard blood-pressure control. N Engl J Med2015;373:2103-16. [PMID: 26551272] doi:10.1056/NEJMoa1511939 CrossrefMedlineGoogle Scholar
    • 10. GBD 2016 Risk Factors CollaboratorsGlobal, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet2017;390:1345-422. [PMID: 28919119] doi:10.1016/S0140-6736(17)32366-8 CrossrefMedlineGoogle Scholar
    • 11. Forouzanfar MH Liu P Roth GA Ng M Biryukov S Marczak L et alGlobal burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA2017;317:165-82. [PMID: 28097354] doi:10.1001/jama.2016.19043 CrossrefMedlineGoogle Scholar
    • 12. Rahimi K Emdin CA MacMahon S The epidemiology of blood pressure and its worldwide management. Circ Res2015;116:925-36. [PMID: 25767281] doi:10.1161/CIRCRESAHA.116.304723 CrossrefMedlineGoogle Scholar
    • 13. Lewington S Clarke R Qizilbash N Peto R Collins R Prospective Studies CollaborationAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet2002;360:1903-13. [PMID: 12493255] CrossrefMedlineGoogle Scholar
    • 14. Rapsomaniki E Timmis A George J Pujades-Rodriguez M Shah AD Denaxas S et alBlood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet2014;383:1899-911. [PMID: 24881994] doi:10.1016/S0140-6736(14)60685-1 CrossrefMedlineGoogle Scholar
    • 15. Tajeu GS Booth JN 3rd Colantonio LD Gottesman RF Howard G Lackland DT et alIncident cardiovascular disease among adults with blood pressure <140/90 mm Hg. Circulation2017;136:798-812. [PMID: 28634217] doi:10.1161/CIRCULATIONAHA.117.027362 CrossrefMedlineGoogle Scholar
    • 16. Karmali KN Ning H Goff DC Lloyd-Jones DM Identifying individuals at risk for cardiovascular events across the spectrum of blood pressure levels. J Am Heart Assoc2015;4:e002126. [PMID: 26391134] doi:10.1161/JAHA.115.002126 CrossrefMedlineGoogle Scholar
    • 17. James PA Oparil S Carter BL Cushman WC Dennison-Himmelfarb C Handler J et al2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA2014;311:507-20. [PMID: 24352797] doi:10.1001/jama.2013.284427 CrossrefMedlineGoogle Scholar
    • 18. Chobanian AV Bakris GL Black HR Cushman WC Green LA Izzo JL Jr et alJoint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureNational Heart, Lung, and Blood Institute. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension2003;42:1206-52. [PMID: 14656957] CrossrefMedlineGoogle Scholar
    • 19. Grundy SM Stone NJ Bailey AL Beam C Birtcher KK Blumenthal RS et al2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol2018. [PMID: 30423391] doi:10.1016/j.jacc.2018.11.002 CrossrefMedlineGoogle Scholar
    • 20. Muntner P Whelton PK Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J Am Coll Cardiol2017;69:2446-56. [PMID: 28494981] doi:10.1016/j.jacc.2017.02.066 CrossrefMedlineGoogle Scholar
    • 21. Chalmers J “Treating hypertension” or “lowering blood pressure”? Extending the concept [Editorial]. Blood Press2002;11:68-70. [PMID: 12035873] CrossrefMedlineGoogle Scholar
    • 22. Reboussin DM Allen NB Griswold ME Guallar E Hong Y Lackland DT et alSystematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation2018;138:e595-e616. [PMID: 30354656] doi:10.1161/CIR.0000000000000601 CrossrefMedlineGoogle Scholar
    • 23. Bangalore S Toklu B Gianos E Schwartzbard A Weintraub H Ogedegbe G et alOptimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med2017;130:707-719.e8. [PMID: 28109971] doi:10.1016/j.amjmed.2017.01.004 CrossrefMedlineGoogle Scholar
    • 24. Bundy JD Li C Stuchlik P Bu X Kelly TN Mills KT et alSystolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol2017;2:775-81. [PMID: 28564682] doi:10.1001/jamacardio.2017.1421 CrossrefMedlineGoogle Scholar
    • 25. Muntner P Carey RM Gidding S Jones DW Taler SJ Wright JT Jr et alPotential U.S. population impact of the 2017 ACC/AHA high blood pressure guideline. J Am Coll Cardiol2018;71:109-18. [PMID: 29146532] doi:10.1016/j.jacc.2017.10.073 CrossrefMedlineGoogle Scholar
    • 26. Victor RG Lynch K Li N Blyler C Muhammad E Handler J et alA cluster-randomized trial of blood-pressure reduction in black barbershops. N Engl J Med2018;378:1291-301. [PMID: 29527973] doi:10.1056/NEJMoa1717250 CrossrefMedlineGoogle Scholar
    • 27. Jaffe MG Lee GA Young JD Sidney S Go AS Improved blood pressure control associated with a large-scale hypertension program. JAMA2013;310:699-705. [PMID: 23989679] doi:10.1001/jama.2013.108769 CrossrefMedlineGoogle Scholar
    • 28. Shahaj O Denneny D Schwappach A Pearce G Epiphaniou E Parke HL et alSupporting self-management for people with hypertension: a meta-review of quantitative and qualitative systematic reviews. J Hypertens2019;37:264-79. [PMID: 30020240] doi:10.1097/HJH.0000000000001867 CrossrefMedlineGoogle Scholar
    • 29. U.S. Preventive Services Task ForceFinal Recommendation Statement. High Blood Pressure in Adults: Screening. Rockville, MD: U.S. Preventive Services Task Force; 2017. Google Scholar
    • 30. Allen NB Siddique J Wilkins JT Shay C Lewis CE Goff DC et alBlood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA2014;311:490-7. [PMID: 24496536] doi:10.1001/jama.2013.285122 CrossrefMedlineGoogle Scholar
    • 31. Julius S Nesbitt SD Egan BM Weber MA Michelson EL Kaciroti N et alTrial of Preventing Hypertension (TROPHY) Study InvestigatorsFeasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med2006;354:1685-97. [PMID: 16537662] CrossrefMedlineGoogle Scholar
    • 32. Batey DM Kaufmann PG Raczynski JM Hollis JF Murphy JK Rosner B et alStress management intervention for primary prevention of hypertension: detailed results from Phase I of Trials of Hypertension Prevention (TOHP-I). Ann Epidemiol2000;10:45-58. [PMID: 10658688] CrossrefMedlineGoogle Scholar
    • 33. Cook NR Cutler JA Obarzanek E Buring JE Rexrode KM Kumanyika SK et alLong term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the Trials of Hypertension Prevention (TOHP). BMJ2007;334:885-8. [PMID: 17449506] CrossrefMedlineGoogle Scholar
    • 34. Pickering TG Hall JE Appel LJ Falkner BE Graves J Hill MN et alRecommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation2005;111:697-716. [PMID: 15699287] MedlineGoogle Scholar
    • 35. Myers MG A short history of automated office blood pressure - 15 years to SPRINT. J Clin Hypertens (Greenwich)2016;18:721-4. [PMID: 27038200] doi:10.1111/jch.12820 CrossrefMedlineGoogle Scholar
    • 36. Johnson KC Whelton PK Cushman WC Cutler JA Evans GW Snyder JK et alSPRINT Research GroupBlood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension2018;71:848-57. [PMID: 29531173] doi:10.1161/HYPERTENSIONAHA.117.10479 CrossrefMedlineGoogle Scholar
    • 37. Melville S Byrd JB Out-of-office blood pressure monitoring in 2018. JAMA2018;320:1805-6. [PMID: 30398589] doi:10.1001/jama.2018.14865 CrossrefMedlineGoogle Scholar
    • 38. McManus RJ Mant J Franssen M Nickless A Schwartz C Hodgkinson J et alTASMINH4 investigatorsEfficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet2018;391:949-59. [PMID: 29499873] doi:10.1016/S0140-6736(18)30309-X CrossrefMedlineGoogle Scholar
    • 39. Angeli F Verdecchia P Gattobigio R Sardone M Reboldi G White-coat hypertension in adults. Blood Press Monit2005;10:301-5. [PMID: 16496443] CrossrefMedlineGoogle Scholar
    • 40. O'Brien E Parati G Stergiou G Asmar R Beilin L Bilo G et alEuropean Society of Hypertension Working Group on Blood Pressure MonitoringEuropean Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens2013;31:1731-68. [PMID: 24029863] doi:10.1097/HJH.0b013e328363e964 CrossrefMedlineGoogle Scholar
    • 41. Franklin SS Thijs L Hansen TW O'Brien E Staessen JA White-coat hypertension: new insights from recent studies. Hypertension2013;62:982-7. [PMID: 24041952] doi:10.1161/HYPERTENSIONAHA.113.01275 CrossrefMedlineGoogle Scholar
    • 42. Stergiou GS Asayama K Thijs L Kollias A Niiranen TJ Hozawa A et alInternational Database on HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO) InvestigatorsPrognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension2014;63:675-82. [PMID: 24420553] doi:10.1161/HYPERTENSIONAHA.113.02741 CrossrefMedlineGoogle Scholar
    • 43. Eguchi K Hoshide S Ishikawa J Ishikawa S Pickering TG Gerin W et alCardiovascular prognosis of sustained and white-coat hypertension in patients with type 2 diabetes mellitus. Blood Press Monit2008;13:15-20. [PMID: 18199919] doi:10.1097/MBP.0b013e3282f13f4a CrossrefMedlineGoogle Scholar
    • 44. Banegas JR Ruilope LM de la Sierra A Vinyoles E Gorostidi M de la Cruz JJ et alRelationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med2018;378:1509-20. [PMID: 29669232] doi:10.1056/NEJMoa1712231 CrossrefMedlineGoogle Scholar
    • 45. Mallion JM Clerson P Bobrie G Genes N Vaisse B Chatellier G Predictive factors for masked hypertension within a population of controlled hypertensives. J Hypertens2006;24:2365-70. [PMID: 17082717] CrossrefMedlineGoogle Scholar
    • 46. Bobrie G Chatellier G Genes N Clerson P Vaur L Vaisse B et alCardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA2004;291:1342-9. [PMID: 15026401] CrossrefMedlineGoogle Scholar
    • 47. de la Sierra A Banegas JR Vinyoles E Segura J Gorostidi M de la Cruz JJ et alPrevalence of masked hypertension in untreated and treated patients with office blood pressure below 130/80 mm Hg [Letter]. Circulation2018;137:2651-3. [PMID: 29712713] doi:10.1161/CIRCULATIONAHA.118.034619 CrossrefMedlineGoogle Scholar
    • 48. Cuspidi C Macca G Sampieri L Fusi V Severgnini B Michev I et alTarget organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J Hypertens2001;19:1539-45. [PMID: 11564972] CrossrefMedlineGoogle Scholar
    • 49. Kario K Pickering TG Umeda Y Hoshide S Hoshide Y Morinari M et alMorning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation2003;107:1401-6. [PMID: 12642361] CrossrefMedlineGoogle Scholar
    • 50. Basile JN Bloch MJ Analysis of recent papers in hypertension: nighttime administration of at least one antihypertensive medication is associated with better blood pressure control and cardiovascular outcomes in patients with type 2 diabetes or chronic kidney disease. J Clin Hypertens (Greenwich)2013;15:2-4. [PMID: 23282118] doi:10.1111/jch.12028 CrossrefMedlineGoogle Scholar
    • 51. Rahman M Greene T Phillips RA Agodoa LY Bakris GL Charleston J et alA trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension2013;61:82-8. [PMID: 23172931] doi:10.1161/HYPERTENSIONAHA.112.200477 CrossrefMedlineGoogle Scholar
    • 52. Poulter NR Savopoulos C Anjum A Apostolopoulou M Chapman N Cross M et alRandomized crossover trial of the impact of morning or evening dosing of antihypertensive agents on 24-hour ambulatory blood pressure. Hypertension2018;72:870-3. [PMID: 30354703] doi:10.1161/HYPERTENSIONAHA.118.11101 CrossrefMedlineGoogle Scholar
    • 53. Cordain L Eaton SB Sebastian A Mann N Lindeberg S Watkins BA et alOrigins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr2005;81:341-54. [PMID: 15699220] CrossrefMedlineGoogle Scholar
    • 54. Mattes RD Donnelly D Relative contributions of dietary sodium sources. J Am Coll Nutr1991;10:383-93. [PMID: 1910064] CrossrefMedlineGoogle Scholar
    • 55. Institute of MedicineSodium Intake in Populations: Assessment of Evidence. Washington, DC: National Academies Pr; 2013. doi:10.17226/18311 CrossrefGoogle Scholar
    • 56. Newberry SJ Chung M Anderson CAM Chen C Fu Z Tang A et alSodium and Potassium Intake: Effects on Chronic Disease Outcomes and Risks. Comparative Effectiveness Review no. 206. (Prepared by the RAND Southern California Evidence-based Practice Center under contract no. 290-2015-00010-I.) AHRQ publication no. 18-EHC009-EF. Rockville, MD: Agency for Healthcare Research and Quality; June 2018. doi:10.23970/AHRQEPCCER206 CrossrefGoogle Scholar
    • 57. O'Donnell M Mente A Rangarajan S McQueen MJ Wang X Liu L et alPURE InvestigatorsUrinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med2014;371:612-23. [PMID: 25119607] doi:10.1056/NEJMoa1311889 CrossrefMedlineGoogle Scholar
    • 58. Mente A O'Donnell M Rangarajan S McQueen M Dagenais G Wielgosz A et alUrinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. Lancet2018;392:496-506. [PMID: 30129465] doi:10.1016/S0140-6736(18)31376-X CrossrefMedlineGoogle Scholar
    • 59. Appel LJ Moore TJ Obarzanek E Vollmer WM Svetkey LP Sacks FM et alA clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med1997;336:1117-24. [PMID: 9099655] CrossrefMedlineGoogle Scholar
    • 60. Bray GA Vollmer WM Sacks FM Obarzanek E Svetkey LP Appel LJ DASH Collaborative Research GroupA further subgroup analysis of the effects of the DASH diet and three dietary sodium levels on blood pressure: results of the DASH-Sodium Trial. Am J Cardiol2004;94:222-7. [PMID: 15246908] CrossrefMedlineGoogle Scholar
    • 61. Whelton PK Appel LJ Espeland MA Applegate WB Ettinger WH Jr Kostis JB et alSodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA1998;279:839-46. [PMID: 9515998] CrossrefMedlineGoogle Scholar
    • 62. Piercy KL Troiano RP Ballard RM Carlson SA Fulton JE Galuska DA et alThe physical activity guidelines for Americans. JAMA2018;320:2020-8. [PMID: 30418471] doi:10.1001/jama.2018.14854 CrossrefMedlineGoogle Scholar
    • 63. Fagrell B De Faire U Bondy S Criqui M Gaziano M Gronbaek M et alThe effects of light to moderate drinking on cardiovascular diseases. J Intern Med1999;246:331-40. [PMID: 10583704] CrossrefMedlineGoogle Scholar
    • 64. Roerecke M Kaczorowski J Tobe SW Gmel G Hasan OSM Rehm J The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health2017;2:e108-e120. [PMID: 29253389] doi:10.1016/S2468-2667(17)30003-8 CrossrefMedlineGoogle Scholar
    • 65. McGuire HL Svetkey LP Harsha DW Elmer PJ Elmer PJ Appel LJ et alComprehensive lifestyle modification and blood pressure control: a review of the PREMIER trial. J Clin Hypertens (Greenwich)2004;6:383-90. [PMID: 15249794] CrossrefMedlineGoogle Scholar
    • 66. Brook RD Appel LJ Rubenfire M Ogedegbe G Bisognano JD Elliott WJ et alAmerican Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical ActivityBeyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. Hypertension2013;61:1360-83. [PMID: 23608661] doi:10.1161/HYP.0b013e318293645f CrossrefMedlineGoogle Scholar
    • 67. Pareek AK Messerli FH Chandurkar NB Dharmadhikari SK Godbole AV Kshirsagar PP et alEfficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol2016;67:379-89. [PMID: 26821625] doi:10.1016/j.jacc.2015.10.083 CrossrefMedlineGoogle Scholar
    • 68. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288:2981-97. [PMID: 12479763] MedlineGoogle Scholar
    • 69. Beckett NS Peters R Fletcher AE Staessen JA Liu L Dumitrascu D et alHYVET Study GroupTreatment of hypertension in patients 80 years of age or older. N Engl J Med2008;358:1887-98. [PMID: 18378519] doi:10.1056/NEJMoa0801369 CrossrefMedlineGoogle Scholar
    • 70. Pitt B Zannad F Remme WJ Cody R Castaigne A Perez A et alThe effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med1999;341:709-17. [PMID: 10471456] CrossrefMedlineGoogle Scholar
    • 71. Zannad F McMurray JJ Krum H van Veldhuisen DJ Swedberg K Shi H et alEMPHASIS-HF Study GroupEplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med2011;364:11-21. [PMID: 21073363] doi:10.1056/NEJMoa1009492 CrossrefMedlineGoogle Scholar
    • 72. Yusuf S Sleight P Pogue J Bosch J Davies R Dagenais G Heart Outcomes Prevention Evaluation Study InvestigatorsEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med2000;342:145-53. [PMID: 10639539] CrossrefMedlineGoogle Scholar
    • 73. Dahlöf B Sever PS Poulter NR Wedel H Beevers DG Caulfield M et alASCOT InvestigatorsPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. [PMID: 16154016] MedlineGoogle Scholar
    • 74. Carey RM Calhoun DA Bakris GL Brook RD Daugherty SL Dennison-Himmelfarb CR et alAmerican Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke CouncilResistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension2018;72:e53-e90. [PMID: 30354828] doi:10.1161/HYP.0000000000000084 CrossrefMedlineGoogle Scholar
    • 75. Funder JW Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control2013;6:129-38. [PMID: 24133375] doi:10.2147/IBPC.S13783 CrossrefMedlineGoogle Scholar
    • 76. Calhoun DA White WB Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens2008;2:462-8. [PMID: 20409927] doi:10.1016/j.jash.2008.05.005 CrossrefMedlineGoogle Scholar
    • 77. Noubiap JJ Nansseu JR Nyaga UF Sime PS Francis I Bigna JJ Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart2019;105:98-105. [PMID: 30087099] doi:10.1136/heartjnl-2018-313599 CrossrefMedlineGoogle Scholar
    • 78. Daugherty SL Powers JD Magid DJ Tavel HM Masoudi FA Margolis KL et alIncidence and prognosis of resistant hypertension in hypertensive patients. Circulation2012;125:1635-42. [PMID: 22379110] doi:10.1161/CIRCULATIONAHA.111.068064 CrossrefMedlineGoogle Scholar
    • 79. Williams B MacDonald TM Morant S Webb DJ Sever P McInnes G et alBritish Hypertension Society's PATHWAY Studies GroupSpironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet2015;386:2059-68. [PMID: 26414968] doi:10.1016/S0140-6736(15)00257-3 CrossrefMedlineGoogle Scholar
    • 80. Krieger EM Drager LF Giorgi DMA Pereira AC Barreto-Filho JAS Nogueira AR et alReHOT InvestigatorsSpironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment). Hypertension2018;71:681-90. [PMID: 29463627] doi:10.1161/HYPERTENSIONAHA.117.10662 CrossrefMedlineGoogle Scholar
    • 81. Byrd JB Turcu AF Auchus RJ Primary aldosteronism. Circulation2018;138:823-35. [PMID: 30359120] doi:10.1161/CIRCULATIONAHA.118.033597 CrossrefMedlineGoogle Scholar
    • 82. Calhoun DA Nishizaka MK Zaman MA Thakkar RB Weissmann P Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension2002;40:892-6. [PMID: 12468575] CrossrefMedlineGoogle Scholar
    • 83. Williams B MacDonald TM Morant SV Webb DJ Sever P McInnes GT et alBritish Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm Based Therapy (PATHWAY) Study GroupEndocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol2018;6:464-75. [PMID: 29655877] doi:10.1016/S2213-8587(18)30071-8 CrossrefMedlineGoogle Scholar
    • 84. Hwang AY Dave C Smith SM Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014. Hypertension2016;68:1349-54. [PMID: 27777360] CrossrefMedlineGoogle Scholar
    • 85. Bress AP Kramer H Khatib R Beddhu S Cheung AK Hess R et alPotential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States: projections from NHANES (National Health and Nutrition Examination Survey). Circulation2017;135:1617-28. [PMID: 28193605] doi:10.1161/CIRCULATIONAHA.116.025322 CrossrefMedlineGoogle Scholar
    • 86. Basu S Sussman JB Rigdon J Steimle L Denton BT Hayward RA Benefit and harm of intensive blood pressure treatment: derivation and validation of risk models using data from the SPRINT and ACCORD trials. PLoS Med2017;14:e1002410. [PMID: 29040268] doi:10.1371/journal.pmed.1002410 CrossrefMedlineGoogle Scholar
    • 87. Phillips RA Xu J Peterson LE Arnold RM Diamond JA Schussheim AE Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension. J Am Coll Cardiol2018;71:1601-10. [PMID: 29525494] doi:10.1016/j.jacc.2018.01.074 CrossrefMedlineGoogle Scholar
    • 88. McEvoy JW Martin SS Dardari ZA Miedema MD Sandfort V Yeboah J et alCoronary artery calcium to guide a personalized risk-based approach to initiation and intensification of antihypertensive therapy. Circulation2017;135:153-65. [PMID: 27881560] doi:10.1161/CIRCULATIONAHA.116.025471 CrossrefMedlineGoogle Scholar
    • 89. Williamson JD Supiano MA Applegate WB Berlowitz DR Campbell RC Chertow GM et alSPRINT Research GroupIntensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA2016;315:2673-82. [PMID: 27195814] doi:10.1001/jama.2016.7050 CrossrefMedlineGoogle Scholar
    • 90. Garrison SR Kolber MR Korownyk CS McCracken RK Heran BS Allan GM Blood pressure targets for hypertension in older adults. Cochrane Database Syst Rev2017;8:CD011575. [PMID: 28787537] doi:10.1002/14651858.CD011575.pub2 CrossrefMedlineGoogle Scholar
    • 91. Chow CK Teo KK Rangarajan S Islam S Gupta R Avezum A et alPURE (Prospective Urban Rural Epidemiology) Study InvestigatorsPrevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA2013;310:959-68. [PMID: 24002282] doi:10.1001/jama.2013.184182 CrossrefMedlineGoogle Scholar
    • 92. Viera AJ Hawes EM Management of mild hypertension in adults. BMJ2016;355:i5719. [PMID: 27872051] doi:10.1136/bmj.i5719 CrossrefMedlineGoogle Scholar
    • 93. Musini VM Gueyffier F Puil L Salzwedel DM Wright JM Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database Syst Rev2017;8:CD008276. [PMID: 28813123] doi:10.1002/14651858.CD008276.pub2 CrossrefMedlineGoogle Scholar
    • 94. Lonn EM Bosch J López-Jaramillo P Zhu J Liu L Pais P et alHOPE-3 InvestigatorsBlood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med2016;374:2009-20. [PMID: 27041480] doi:10.1056/NEJMoa1600175 CrossrefMedlineGoogle Scholar
    • 95. Jamerson K Weber MA Bakris GL Dahlöf B Pitt B Shi V et alACCOMPLISH Trial InvestigatorsBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med2008;359:2417-28. [PMID: 19052124] doi:10.1056/NEJMoa0806182 CrossrefMedlineGoogle Scholar
    • 96. Brook RD Weder AB Initial hypertension treatment: one combination fits most? [Editorial]. J Am Soc Hypertens2011;5:66-75. [PMID: 21414561] doi:10.1016/j.jash.2011.01.002 CrossrefMedlineGoogle Scholar